rs1260326, GCKR

N. diseases: 81
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Colorectal Carcinoma
CUI: C0009402
Disease: Colorectal Carcinoma
0.010 GeneticVariation BEFREE Among the 19 CRP-associated SNPs, rs1260326 and rs6734238 were significantly associated with CRC risk (P = 7.5 × 10-4, and P = 0.003, respectively). 30476131 2019
Osteoarthritis, Knee
CUI: C0409959
Disease: Osteoarthritis, Knee
0.010 GeneticVariation BEFREE With respect to gene-gene interactions, the pairwise interactions of rs112129861 (PDZK1) and rs7193778 (IGF1R); rs17050272 (INHBB) and rs1106766 (R3HDM2); rs1106766 (R3HDM2) and rs780093 (GCKR); rs1260326 (GCKR) and rs17786744 (STC1); and rs17786744 (STC1) and rs1106766 (R3HDM2) make it possible to visualize the synergistic or antagonistic effect of their genotypes or alleles on KOA development. 29855200 2019
Nonalcoholic Steatohepatitis
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
0.010 GeneticVariation BEFREE The GCKR rs1260326 and rs780094 allele T were associated with susceptibility to NAFLD (OR 1.49, 95 % CI 1.09-2.05, p = 0.012; and OR 1.51, 95 % CI 1.09-2.09, p = 0.013, respectively), non-alcoholic steatohepatitis (NASH) (OR 1.55, 95 % CI 1.10-2.17, p = 0.013; and OR 1.56, 95 % CI 1.10-2.20, p = 0.012, respectively) and NASH with significant fibrosis (OR 1.50, 95 % CI 1.01-2.21, p = 0.044; and OR 1.52, 95 % CI 1.03-2.26, p = 0.038, respectively). 23800943 2014
Monogenic diabetes
CUI: C3888631
Disease: Monogenic diabetes
0.010 GeneticVariation BEFREE The study group included 129 children with GCK-MODY from the Polish Registry of Monogenic Diabetes and 395 with type 1 diabetes (T1DM), in whom we genotyped 2 SNPs in G6PC2 (rs560887) and GCKR (rs1260326). 24918535 2014
Diabetes Mellitus, Insulin-Dependent
0.010 GeneticVariation BEFREE The study group included 129 children with GCK-MODY from the Polish Registry of Monogenic Diabetes and 395 with type 1 diabetes (T1DM), in whom we genotyped 2 SNPs in G6PC2 (rs560887) and GCKR (rs1260326). 24918535 2014
Diabetes
CUI: C0011847
Disease: Diabetes
0.010 GeneticVariation BEFREE The intronic single-nucleotide polymorphism (SNP) rs780094 (intron 16) and the missense SNP rs1260326 (P446L) in the GCKR gene are strongly associated with increased circulating triglyceride and C-reactive protein levels and, paradoxically, reductions in diabetes incidence, fasting glucose levels, and insulin resistance. 21525158 2011
Myocardial Ischemia
CUI: C0151744
Disease: Myocardial Ischemia
0.010 GeneticVariation BEFREE In the general population, both TRIB1-rs2954029 and GCKR-rs1260326 were associated with lipid levels, whereas TRIB1 was also associated with increased risk of IHD and MI. 21071687 2011
Myocardial Infarction
CUI: C0027051
Disease: Myocardial Infarction
0.010 GeneticVariation BEFREE In the general population, both TRIB1-rs2954029 and GCKR-rs1260326 were associated with lipid levels, whereas TRIB1 was also associated with increased risk of IHD and MI. 21071687 2011
Hyperglycemia
CUI: C0020456
Disease: Hyperglycemia
0.010 GeneticVariation BEFREE Moreover, an additive effect of GCKR rs1260326(T) and GCK (-30G) alleles conferred lower fasting glycemia (P = 1 x 10(-13)), insulinemia (P = 5 x 10(-6)), and hyperglycemia risk (P = 1 x 10(-6)). 18556336 2008
Fatty Liver
CUI: C0015695
Disease: Fatty Liver
0.020 GeneticVariation BEFREE Metabolic effects of LYPLAL1 rs12137855-C were similar, but statistically less robust, to the effects of GCKR rs1260326-T. TM6SF2 rs58542926-T displayed opposite metabolic effects when compared with the fatty liver associations. 29648650 2018
Gestational Diabetes
CUI: C0085207
Disease: Gestational Diabetes
0.020 GeneticVariation BEFREE No associations between FTO rs9939609 and rs8050136, GCKR rs1260326 and GDM risk were found. 30074065 2018
Gestational Diabetes
CUI: C0085207
Disease: Gestational Diabetes
0.020 GeneticVariation BEFREE Several variants <i>PPARG2</i> rs1801282 (<i>C>G</i>); <i>PPARGC1A</i> rs8192678 (<i>C>T</i>); <i>TCF7L2</i> rs7903146 (<i>C>T</i>); <i>LDLR</i> rs2228671 (<i>C>T</i>); <i>MTHFR</i> rs1801133 (<i>C>T</i>); <i>APOA5</i> rs662799 (<i>T>C</i>); <i>GCKR</i> rs1260326 (<i>C>T</i>); <i>FTO</i> rs9939609 (<i>T>A</i>); <i>MC4R</i> rs17782313 (<i>T>C</i>) were genotyped in 168 pregnant Caucasian women with or without GDM by High Resolution Melting (HRM) analysis. 28133617 2017
Fatty Liver Disease
CUI: C4529962
Disease: Fatty Liver Disease
0.020 GeneticVariation BEFREE This study suggests that risk allele T of the GCKR rs780094 and rs1260326 is associated with predisposition to NAFLD and NASH with significant fibrosis. 23800943 2014
Fatty Liver Disease
CUI: C4529962
Disease: Fatty Liver Disease
0.020 GeneticVariation BEFREE Herein, we aimed to study the association between hepatic fat accumulation as assessed by magnetic resonance imaging and circulating levels of cytokeratin-18 (CK-18) fragments, a robust NASH biomarker, and to explore the impact on this association of ethnicity, insulin resistance, and single nucleotide polymorphisms (SNPs) associated with steatosis (rs738409 in the PNPLA3, rs1260326 in the GCKR) or NASH severity (rs2645424 in the FDFT1). 23275357 2013
Fatty Liver
CUI: C0015695
Disease: Fatty Liver
0.020 GeneticVariation BEFREE The rs1260326 was associated with elevated triglycerides (Caucasians P = 0.00014; African Americans P = 0.00417), large very low-density lipoprotein (VLDL) (Caucasians P = 0.001; African Americans, P = 0.03), and with fatty liver (Caucasians P = 0.034; African Americans P = 0.00002; and Hispanics P = 0.016). 22105854 2012
Obesity
CUI: C0028754
Disease: Obesity
0.030 GeneticVariation BEFREE Here we show that adiposity significantly amplifies the effect of three sequence variants (encoding PNPLA3 p.I148M, TM6SF2 p.E167K, and GCKR p.P446L) associated with nonalcoholic fatty liver disease (NAFLD). 28436986 2017
Obesity
CUI: C0028754
Disease: Obesity
0.030 GeneticVariation BEFREE We investigated whether a 1-year intensive lifestyle intervention (ILI) for weight loss would avert the unfavorable cardiometabolic effects associated with GCKR Leu446Pro when compared with a diabetes mellitus support and education arm in overweight/obese individuals with type 2 diabetes mellitus with triglyceride (n=3214) and CRP (n=1411) data participating in a randomized lifestyle intervention study for weight loss, Action for Health in Diabetes Mellitus (Look AHEAD). 26578543 2016
Diabetes Mellitus
CUI: C0011849
Disease: Diabetes Mellitus
0.030 GeneticVariation BEFREE We investigated whether a 1-year intensive lifestyle intervention (ILI) for weight loss would avert the unfavorable cardiometabolic effects associated with GCKR Leu446Pro when compared with a diabetes mellitus support and education arm in overweight/obese individuals with type 2 diabetes mellitus with triglyceride (n=3214) and CRP (n=1411) data participating in a randomized lifestyle intervention study for weight loss, Action for Health in Diabetes Mellitus (Look AHEAD). 26578543 2016
Diabetes Mellitus
CUI: C0011849
Disease: Diabetes Mellitus
0.030 GeneticVariation BEFREE Five gout susceptibility loci were identified at the genome-wide significance level (p<5.0×10(-8)), which contained well-known urate transporter genes (ABCG2 and SLC2A9) and additional genes: rs1260326 (p=1.9×10(-12); OR=1.36) of GCKR (a gene for glucose and lipid metabolism), rs2188380 (p=1.6×10(-23); OR=1.75) of MYL2-CUX2 (genes associated with cholesterol and diabetes mellitus) and rs4073582 (p=6.4×10(-9); OR=1.66) of CNIH-2 (a gene for regulation of glutamate signalling). 25646370 2016
Dyslipidemias
CUI: C0242339
Disease: Dyslipidemias
0.030 GeneticVariation BEFREE There were significant associations between rs1260333 (OR is 0.82, 95 % CI 0.74-0.92, p ~ 3.96 × 10(-4)), rs1260326 (OR is 0.82, 95 % CI 0.74-0.92, p ~ 5.31 × 10(-4)), and rs964184 (OR is 1.36, 95 % CI 1.20-1.55, p ~ 1.89 × 10(-6)) and dyslipidemia. 23832694 2013
Diabetes Mellitus
CUI: C0011849
Disease: Diabetes Mellitus
0.030 GeneticVariation BEFREE The intronic single-nucleotide polymorphism (SNP) rs780094 (intron 16) and the missense SNP rs1260326 (P446L) in the GCKR gene are strongly associated with increased circulating triglyceride and C-reactive protein levels and, paradoxically, reductions in diabetes incidence, fasting glucose levels, and insulin resistance. 21525158 2011
Obesity
CUI: C0028754
Disease: Obesity
0.030 GeneticVariation BEFREE Results of logistic regression revealed that, despite higher triglyceride levels, the carriers of the GCKR variants were more protected against the development of obesity; the adjusted models confirmed the lower risk of obesity for both variants (rs1260326: OR, 0.46; 95% CI, 0.25-0.83; rs780094: OR, 0.41; 95% CI, 0.23-0.74). 21511510 2011
Dyslipidemias
CUI: C0242339
Disease: Dyslipidemias
0.030 GeneticVariation BEFREE We evaluated, in a general French population, the contribution of the GCKR rs1260326-P446L polymorphism to quantitative metabolic parameters and to dyslipidemia and hyperglycemia risk. 18556336 2008
Dyslipidemias
CUI: C0242339
Disease: Dyslipidemias
0.030 GeneticVariation BEFREE A polymorphism in the GCKR gene predicted dyslipidaemia (rs1260326, OR 1.15, 95% CI 1.09-1.22, p < 0.00001) but not the metabolic syndrome. 18853134 2008
Steatohepatitis
CUI: C2711227
Disease: Steatohepatitis
0.040 GeneticVariation BEFREE Metabolic effects of LYPLAL1 rs12137855-C were similar, but statistically less robust, to the effects of GCKR rs1260326-T. TM6SF2 rs58542926-T displayed opposite metabolic effects when compared with the fatty liver associations. 29648650 2018